Bicara Therapeutics Inc.
Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
About
CEO
Ms. Claire Mazumdar Clemon M.B.A., Ph.D.
Employees
32
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
116 Huntington Avenue, Boston, MA 02116, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 12, 2024 | -0.46 | -1.60 | -1.14 | 247.83% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 1 | — | 3 |
| Average estimate | — | -0.38 | — | -1.47 |
| Low estimate | — | -0.38 | — | -1.58 |
| High estimate | — | -0.38 | — | -1.42 |
| Last year EPS | — | — | — | -2.74 |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
46.160%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | |
|---|---|
| Fiscal date | 2023-12-31 |
| Total reported revenue | — |
| Cost of revenue | — |
| Gross profit | — |
| Operating expense | |
| Research & development | 30.62M |
| Selling general and admin | 9.27M |
| Other operating expenses | — |
| Operating income | -39.89M |
| Non operating interest income | |
| Income | 1.31M |
| Expense | — |
| Other income expense | -13.41M |
| Pretax income | -51.98M |
| Tax provision | 5,000 |
| Net income | -51.99M |
| Basic EPS | -3.37 |
| Diluted EPS | -3.37 |
| Basic average shares | 15.44M |
| Diluted average shares | 15.44M |
| EBITDA | -51.96M |
| Net income from continuing op. | -51.99M |
| Minority interests | — |
| Preferred stock dividends | — |
Balance sheet
| 2023 | 2022 | |
|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 |
| Total assets | 233.98M | 6.70M |
| Current assets | ||
| Cash | — | — |
| Cash equivalents | — | — |
| Cash and cash equivalents | 230.44M | 4.16M |
| Other short term investments | — | — |
| Accounts receivable | — | — |
| Other receivables | — | — |
| Inventory | — | — |
| Prepaid assets | — | — |
| Restricted cash | — | — |
| Assets held for sale | — | — |
| Hedging assets | — | — |
| Other current assets | 633,000 | 826,000 |
| Non current assets | ||
| Properties | 815,000 | 636,000 |
| Land and improvements | — | — |
| Machinery furniture equipment | — | — |
| Construction in progress | — | — |
| Leases | — | — |
| Accumulated depreciation | — | — |
| Goodwill | — | — |
| Investment properties | — | — |
| Financial assets | — | — |
| Intangible assets | — | — |
| Investments and advances | — | — |
| Other non current assets | 2.09M | 1.08M |
| Total liabilities | 382.75M | 105.51M |
| Current liabilities | ||
| Accounts payable | 3.19M | 5.14M |
| Accrued expenses | 9.87M | 17.58M |
| Short term debt | 285,000 | — |
| Deferred revenue | — | — |
| Tax payable | — | — |
| Pensions | 1.74M | 1.18M |
| Other current liabilities | — | — |
| Non current liabilities | ||
| Long term debt | 372,000 | — |
| Provision for risks and charges | — | — |
| Deferred liabilities | — | — |
| Derivative product liabilities | — | — |
| Other non current liabilities | 17,000 | 85,000 |
| Shareholders equity | ||
| Common stock | 2,000 | 2,000 |
| Retained earnings | -153.02M | -101.04M |
| Other shareholders equity | — | — |
| Total shareholders equity | -148.77M | -98.80M |
| Additional paid in capital | 4.25M | 2.23M |
| Treasury stock | — | — |
| Minority interest | — | — |
Cash flow statement
| 2023 | |
|---|---|
| Operating Activities | |
| Net Income | -51.99M |
| Depreciation | 19,000 |
| Deferred Taxes | — |
| Stock-Based Compensation | 1.90M |
| Other Non-Cash Items | 13.50M |
| Accounts Receivable | — |
| Accounts Payable | — |
| Other Assets & Liabilities | -47,000 |
| Operating Cash Flow | -36.62M |
| Investing Activities | |
| Capital Expenditures | -586,000 |
| Net Intangibles | — |
| Net Acquisitions | — |
| Purchase of Investments | — |
| Sale of Investments | — |
| Investing Cash Flow | -586,000 |
| Financing Activities | |
| Long-Term Debt Issuance | — |
| Long-Term Debt Payments | — |
| Other Financing Charges | — |
| Financing Cash Flow | 272.35M |
| Other Cash Details | |
| End Cash Position | 230.44M |
| Income Tax Paid | — |
| Interest Paid | — |
| Free Cash Flow | -46.21M |
Error: Invalid format in Holders JSON file.
Article
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC). The results were presented in a poster session during the 2025 ASCO Gastrointestinal (GI) Cancers Symposium on Saturday, January 25, 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β), and is being evaluated in multiple solid tumor types.
Jan 27, 2025
Article
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
Nov 12, 2024
Article
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET.
Nov 11, 2024
